Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:BCAB

BioAtla Q3 2026 Earnings Date & Estimates

BioAtla logo
$1.31 -0.05 (-3.68%)
As of 03:50 PM Eastern

BioAtla is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from BioAtla in Q3 2026

BioAtla is expected to post earnings of -$7.00 per share on revenue of $5.59 million. In the same quarter a year earlier BioAtla reported -$13.50 per share. BioAtla last reported on August 13, 2026, posting $0.14 per share and beating the -$8.50 consensus estimate. BioAtla has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$7.00
Expected Revenue
$5.59 million
Prior-Year EPS
-$13.50

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.14 (Beat by +$8.64)
Last Quarter Revenue
$6.50 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

BioAtla Q3 2026 Earnings FAQ

BioAtla (NASDAQ:BCAB) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

BioAtla's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect BioAtla to post earnings of -$7.00 per share for Q3 2026.

The consensus revenue estimate for BioAtla is $5.59 million for Q3 2026.

BioAtla Earnings Headlines

Contrasting BioAtla (NASDAQ:BCAB) and Bicycle Therapeutics (NASDAQ:BCYC)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110357
BioAtla Announces $40 Million Oncology SPV Investment Deal
May 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BCAB/pressreleases/36851340/bioatla-announces-40-million-oncology-spv-investment-deal/
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
October 19 at 1:00 AM  |  Altimetry (Ad)
BioAtla Announces Share Consolidation
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266037/0/en/bioatla-announces-share-consolidation.html
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266019/0/en/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights.html
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value
March 2, 2026  |  quiverquant.comQ
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB) was a biotechnology company focused on developing antibody-based cancer therapies. The company’s research centered on its Conditionally Active Biologics (CAB) platform, which was designed to create therapeutic antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissue.

BioAtla’s development pipeline included antibody-drug conjugates and other immuno-oncology candidates. Its leading programs included mecbotamab vedotin, also known as BA3011, an antibody-drug conjugate targeting AXL, and ozuriftamab vedotin, or BA3021, an antibody-drug conjugate directed at ROR2. The company evaluated these candidates in clinical studies for solid tumors and other cancers.

Founded in 2007 and headquartered in San Diego, California, BioAtla advanced its programs through clinical development and collaborations intended to support the development of targeted cancer medicines. The company later reduced operations and pursued strategic alternatives after encountering clinical and financial challenges. Public disclosures indicated that BioAtla ultimately wound down its business, so its historical pipeline and platform provide the primary basis for describing the company.

View BioAtla Profile
Earnings Tools